Emma Rousseau

Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models

Sheryl M. Gough, John J. Flanagan, Jessica L.F. Teh et al. · Clinical Cancer Research · 2024 · 160 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer

JJ Flanagan, Yimin Qian, SM Gough et al. · Cancer Research · 2019 · 133 citations

Medicine, Biochemistry, Endocrinology +16

Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers

Jennifer Cantley, Xiaofen Ye, Emma Rousseau et al. · Nature Communications · 2022 · 129 citations · Full text

Pharmacy, Molecular Biology, Oncology +14

Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer

Lawrence B. Snyder, John J. Flanagan, Yimin Qian et al. · Cancer Research · 2021 · 110 citations

Life Sciences, Biochemistry, Endocrinology +15

PROTACs Targeting BRM (SMARCA2) Afford Selective <i>In Vivo</i> Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models

Michael Berlin, Jennifer Cantley, Mark Bookbinder et al. · Journal of Medicinal Chemistry · 2024 · 30 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +6